BFBruno Frediani

Bruno Frediani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bruno Frediani has a total of 81 co-authors. Here are the top co-authors by number of shared publications:

  • Luca Cantarini

    Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy

    8 shared publications
  • Claudia Fabiani

    Ophthalmology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy

    7 shared publications
  • Antonio Vitale

    Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy

    5 shared publications
  • Jurgen Sota

    From the Rheumatology Unit, Department of Medical Sciences (C.G., J.S., A.V., S.G., V.C., J.S., B.F., L.C.), Surgery and Neuroscience, University of Siena, Siena University Hospital, European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center, Siena, Italy

    5 shared publications
  • Donato Rigante

    Department of Life Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy

    3 shared publications
  • Edoardo Conticini

    Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy

    3 shared publications

Latest Publications

  • Difficult-to-Treat Concept in Psoriatic Arthritis: Analysis of 2 Potential Definitions in a Large Group of Patients. A Cross-Sectional Study

    by Fabio Massimo Perrotta, Stefano Gentileschi, Silvia Scriffignano, Riccardo Terribili, Elena Bianchi, Bruno Frediani, Ennio Lubrano

    Objective: The main aim of the study was to evaluate the performance of 2 proposed criteria for difficult-to-treat (D2T) psoriatic arthritis (PsA) in a group of patients and to evaluate the agreement between the 2 sets of criteria.Methods: We performed a cross-sectional analysis of 2 longitudinal cohorts of patients with PsA fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR), with at least 1 year of follow-up. A detailed medical history was collected and a physical examination was performed for all recruited patients. The proposed criteria for patients with D2T PsA were applied in our group. To test the performance of the 2 sets of criteria, we used an external validator (absence of patient acceptable symptom state + physician global assessment ≥ 6 cm). Finally, the agreement between the 2 sets of criteria was assessed.Results: We evaluated 378 patients with PsA (219 male/159 female), with a mean age (range) of 58 (19-75) years. Seventy-five (19.8%) patients fulfilled the D2T criteria proposed by Perrotta et al and 58 (15.3%) the D2T criteria proposed by Kumthekar et al. Both criteria showed comparable performance, with low sensitivity (Perrotta: 37.8%, Kumthekar: 29.7%) but good specificity (Perrotta: 82.1%, Kumthekar: 86.2%). Finally, the agreement between the 2 sets of criteria is substantial (Fleiss 0.72), suggesting that both criteria identify nearly the same group of patients.Conclusion: Our study compared 2 published sets of criteria showing comparable performance and substantial agreement. This study may pave the way for further research in this field.


  • Comparing biologic options for the management of Behcet’s disease-related uveitis

    by Antonio Vitale, Valeria Caggiano, Virginia Berlengiero, Maria Orsetta Perfetti, Jurgen Sota, Gian Marco Tosi, Bruno Frediani, Luca Cantarini, Claudia Fabiani

    : Behçet’s disease (BD) associated uveitis occurs in approximately 50-70% of patients. Ocular involvement in BD may induce a severe affection of visual function, leading to a considerable decrease ...


  • Open Access

    High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab

    by Edoardo Conticini, Federico Franchi, David Bennett, Serafina Valente, Maria A Mazzei, Elena Bargagli, Luca Volterrani, Sabino Scolletta, Bruno Frediani


  • The Role of Biologic Agents in the Management of Pediatric-Onset Noninfectious Posterior Scleritis

    by Carla Gaggiano, Virginia Berlengiero, Antonio Vitale, Maria Tarsia, Salvatore Grosso, Gian Marco Tosi, Francesca Ricci, Jurgen Sota, Valeria Caggiano, Bruno Frediani, et al.

    Registry-based observational prospective study aimed at describing the use of biologic drugs in pediatric-onset scleritis. Data were collected at baseline, at 3-, 6-, 12-month follow-up and at last assessment. Scleral inflammation was graded according to Sen classification. Five patients (9 eyes) treated with adalimumab, infliximab, abatacept and secukinumab were included. All patients were previously treated with conventional immunosuppressors and glucocorticoids. Median biologic treatment duration was 28 (IQR = 118) months. At 6-months, scleritis resolved in all eyes. At 12-months, complete disease control was observed in 7/9 eyes (77.8%). The number of relapses 12 months before and after treatment initiation was 17 and 2, respectively. Mean BCVA was 0.83 (range 0.3–1.0) at baseline and 1.0 for all eyes after 12 months. Glucocorticoids had been withdrawn in 4/5 patients. In conclusion, biological agents proved to be effective in pediatric-onset scleritis, allowing a noticeable steroid-sparing effect and preserving visual function and bulbar integrity.


  • Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis

    by E Conticini, B Hellmich, B Frediani, E Csernok, C Löffler

    There is a strong unmet need for biomarkers in giant cell arteritis (GCA), as C-reactive protein (CRP) may be unreliable in patients treated with Tocilizumab (TCZ). We aimed to assess whether C3 an...


  • Pediatric Scleritis: An Update

    by Maria Tarsia, Carla Gaggiano, Elisa Gessaroli, Salvatore Grosso, Gian Marco Tosi, Bruno Frediani, Luca Cantarini, Claudia Fabiani

    Posterior idiopathic scleritis is the most common type of scleritis observed in childhood. Nevertheless, anterior and even necrotizing inflammatory scleritis may occur as well. Although less frequently than in the adult population, scleral inflammation can be associated with systemic disorders, which should be promptly recognized and treated to avoid both ocular and systemic complications. Hence, a multidisciplinary diagnostic work-up should be performed to rule out primarily infectious and autoimmune causes, such as viral and bacterial infections, anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, pediatric sarcoidosis, Behçet’s disease and HLA-B27-associated diseases. Treatment of scleritis should aim to control ocular inflammation, relieve symptoms and prevent relapses, to avoid complications, preserve visual acuity and improve the child’s quality of life. It should be tailored to the patient, considering the type and severity of scleritis, the possible identification of an infectious cause or the presence of an associated rheumatologic condition.


  • Open Access

    Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review

    by Jurgen Sota, Matteo-Maria Girolamo, Bruno Frediani, Gian Marco Tosi, Luca Cantarini, Claudia Fabiani

    Scleritis refers to a wide spectrum of ocular conditions ranging from mild to sight-threatening scleral inflammation that may compromise visual function and threaten the anatomical integrity of the ocular globe. Most aggressive forms like necrotizing or posterior scleritis are often difficult-to-treat cases, refractory to conventional treatment. The association with systemic diseases, namely rheumatoid arthritis, Sjögren syndrome, granulomatosis with polyangiitis, and relapsing polychondritis, may have prognostic implications as well. A better understanding of the pathogenesis of ocular inflammatory diseases have paved the way to more effective and targeted treatment approaches. In this regard, a growing body of evidence supports the potential role of biologic agents in the management of non-infectious scleral inflammation, either idiopathic or in a background of immune-mediated systemic disorders. Biologic agents such as anti-tumor necrosis factor agents, interleukin-1 and interleukin-6 inhibitors as well as CD20 blockade have displayed promising results. More specifically, several studies have reported their ability to control scleral inflammation, reduce the overall scleritis relapses, and allow a glucocorticoid-sparing effect while being generally well tolerated. Anecdotal reports have also been described with other biologic agents including abatacept, ustekinumab, daclizumab, and alemtuzumab as well as targeted small molecules such as tofacitinib. Further studies are warranted to fully elucidate the role of biologic agents in non-infectious scleritis and investigate specific areas with the aim to administer treatments in the context of personalized medicine. This review summarizes the available data regarding clinical trials, small pilot studies, and real-life experience of the last two decades reporting the use of biologic agents in the management of non-infectious scleritis.


  • Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry

    by Marco Sebastiani, Vincenzo Venerito, Serena Bugatti, Chiara Bazzani, Martina Biggioggero, Luca Petricca, Rosario Foti, Alessandra Bortoluzzi, Silvia Balduzzi, Elisa Visalli, et al.

    Objectives EULAR recommendations do not suggest which biologic disease-modifying anti-rheumatic drug (bDMARD) should be preferred after failure of a first bDMARD in the treatment of rheumatoid arthritis (RA). In particular, few data are available regarding the effectiveness of a second-line bDMARD after failure of abatacept (ABA), tocilizumab (TCZ), and rituximab (RTX). The aim of this study was to analyze the retention rate of a second line with tumor necrosis factor inhibitors (TNFi) or other mechanisms of action (MoAs), after the failure of either RTX, TCZ, or ABA. Methods Two hundred and seventy-eight RA patients from the Italian GISEA registry were included in the study. RTX was the first bDMARD in 18% of patients, ABA in 45.7%, and TCZ in 36.3%, while the second bDMARD was a TNFi (group 1) in 129 patients and an agent with a different MoA (group 2) in 149. Results During a median follow-up of 22 months (IQR 68), 129 patients discontinued their treatment; patients of group 1 discontinued the treatment more frequently than patients of group 2 (pp• A large proportion of rheumatoid arthritis patients fail the first biologic DMARD. • Few data are available about the efficacy of biologic DMARD after the failure of a non-TNF inhibitor. • Abatacept, rituximab, or tocilizumab seem to maintain a good retention rate after the failure of a first-course therapy with a non-TNF inhibitor.


  • Crowned Dens Syndrome Presenting as Hemiplegia and Hypoesthesia

    by Edoardo Conticini, Vito Di Martino, Renato De Stefano, Bruno Frediani, Luca Volterrani, Maria Antonietta Mazzei


  • Open Access

    Correction to: Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease

    by Antonio Vitale, Giacomo Emmi, Giuseppe Lopalco, Claudia Fabiani, Stefano Gentileschi, Elena Silvestri, Gerardo Di Scala, Florenzo Iannone, Bruno Frediani, Mauro Galeazzi, et al.

    In the original version of this article the author name Gerardo Di Scala was originally presented incorrectly as ‘Di Scala Gerardo’; this has been corrected in this article.